Protein Programs Connective Tissue Cells in Organ Scarring

by Mohamed Fathima S on  February 6, 2019 at 4:27 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Many chronic diseases occurring in organs are caused due to increased deposition of connective tissue followed by scarring. Now, researchers have uncoded a molecular network that is responsible for these processes and could also lead to new therapies in the future for organ scarring. According to the study, a protein known as PU.1 causes pathological deposition of connective tissue.
Protein Programs Connective Tissue Cells in Organ Scarring
Protein Programs Connective Tissue Cells in Organ Scarring

The increased deposition of connective tissue is a problem in chronic diseases of many organs such as the lungs (idiopathic pulmonary fibrosis), liver (cirrhosis), kidneys (kidney fibrosis), gut (graft versus host disease), and the skin (systemic sclerosis). Up to 40 percent of all deaths in industrial nations are caused by the deposition of connective tissue with subsequent tissue scarring.

In connective tissue diseases such as systemic sclerosis, referred to collectively as 'fibrosis', excessive activation of connective tissue cells leads to hardening of the tissue and scarring within the affected organ. In principle, these diseases can affect any organ system and very often lead to disruption of organ function. Connective tissue cells play a key role in normal wound healing in healthy individuals. However, if the activation of connective tissue cells cannot be switched off, fibrotic diseases occur, in which an enormous amount of matrix is deposited in the tissue, leading to scarring and dysfunction of the affected tissue. Until now, scientists did not fully understand why repair processes malfunction in fibrotic diseases.

An international team of scientists led by Dr. Andreas Ramming from the Chair of Internal Medicine III at FAU has now been able to decipher a molecular mechanism responsible for the ongoing activation of connective tissue cells. In experimental studies, the researchers targeted the protein PU.1. In normal wound healing, the formation of PU.1 is inhibited by the body so that at the end of the normal healing process the connective tissue cells can return to a resting state.

'We were able to show that PU.1 is activated in various connective tissue diseases in the skin, lungs, liver and kidneys. PU.1 binds to the DNA in the connective tissue cells and reprograms them, resulting in a prolonged deposition of tissue components,' explains Dr. Ramming. PU.1 is not the only factor involved in fibrosis, as factors that are involved in the deposition of scar tissue have already been identified in the past. What has been discovered now, however, is that PU.1 plays a central role in a network of factors controlling this process. 'PU.1 is like the conductor in an orchestra,' explains Ramming, 'if you take it out, the entire concert collapses.' This approach has already been tested using an experimental drug, fuelling the hope that clinical trials on inhibiting PU.1 may soon be able to be launched, aimed at treating fibrosis better.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Tongue Abnormalities Parkinsons Disease Surgical Treatment Ganglion Cysts - Ganglion Wrist Magical Millets for Your Health Baby Food - Basics Diet and Nutrition Tips for Athletes Nutrition IQ Tendinitis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive